Advertisement
Advertisement
SRPT
Sarepta Therapeutics,, Inc. Common Stock
16.80
USDSponsored
-0.16
-0.94%
May 22, 15:59 UTC -4
Closed
After-Market
16.89
+0.09
+0.51%
SRPT Earnings Reports
Positive Surprise Ratio
SRPT beat 19 of 42 last estimates.
45%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$371.52M
/$0.21
Implied change from Q1 26 (Revenue/ EPS)
-49.16%
/-92.71%
Implied change from Q2 25 (Revenue/ EPS)
-39.20%
/-88.89%
Sarepta Therapeutics,, Inc. Common Stock earnings per share and revenue
On May 06, 2026, SRPT reported earnings of 2.88 USD per share (EPS) for Q1 26, beating the estimate of 1.01 USD, resulting in a 184.67% surprise. Revenue reached 730.80 million, compared to an expected 464.98 million, with a 57.17% difference. The market reacted with a -9.68% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 17 analysts forecast an EPS of 0.21 USD, with revenue projected to reach 371.52 million USD, implying an decrease of -92.71% EPS, and decrease of -49.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
Rein Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.19
Surprise
+61.98%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
GT Biopharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.11
Surprise
-34.80%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Sarepta Therapeutics,, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Sarepta Therapeutics,, Inc. Common Stock reported EPS of $2.88, beating estimates by 184.67%, and revenue of $730.80M, 57.17% above expectations.
How did the market react to Sarepta Therapeutics,, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -9.68%, changed from $23.03 before the earnings release to $20.80 the day after.
When is Sarepta Therapeutics,, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Sarepta Therapeutics,, Inc. Common Stock's next earnings report?
Based on 17
analysts, Sarepta Therapeutics,, Inc. Common Stock is expected to report EPS of $0.21 and revenue of $371.52M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement